Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Antifibrinolytic drugs are used to decrease perioperative bleeding and allogeneic
transfusions. The extensively studied antifibrinolytic drug aprotinin is efficacious but
expensive, and has been proved to link to higher risks of serious side effects including
renal problems, myocardial events, and strokes in patients undergoing CABG. After the
secession of aprotinin in 2007, a marked increase of blood loss and transfusions in cardiac
surgery took place. An effective and secure hemostatic agent is badly needed. Ulinastatin,
urinary trypsin inhibitor(UTI), is a secreted Kunitz-type protease inhibitor with a wide
inhibition spectrum, including plasmin. Limited studies offered clues to its antifibrinolytic
effect. Tranexamic acid has been applied for years with convinced efficacy and safety. The
objective of the study is to evaluate the hemostatic effect of ulinastatin and tranexamic
acid in cardiac surgery.
Phase:
N/A
Details
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital